Stefan Oschmann, born on July 25, 1957 in Würzburg, Germany, has been Chairman of the Executive Board and CEO of Merck KGaA, Darmstadt, Germany, since May 2016. Previously, Stefan Oschmann served as the Vice Chairman and Deputy CEO. In this role he was responsible for strategy development at Merck KGaA, Darmstadt, Germany.
Stefan Oschmann joined Merck KGaA, Darmstadt, Germany, in 2011 as CEO of the Biopharma division and member of the Executive Board. He led the transformation of Biopharma by optimizing its cost structure and improving the efficiency of its research & development model, including a clear portfolio prioritization. From 2013 to 2014 he was responsible for the Healthcare business sector of Merck KGaA, Darmstadt, Germany. In that role he oversaw the Biopharma, Consumer Health, Allergopharma, and Biosimilars businesses.
Before joining Merck KGaA, Darmstadt, Germany, Stefan Oschmann worked for the U.S. pharma company MSD, where he served as President of Emerging Markets. Other positions included member of senior management and corporate officer with responsibility for the business in Europe, the Middle East, Africa and Canada; Senior Vice President in charge of Worldwide Human Health Marketing as well as Vice President of Europe and the German business.
Stefan Oschmann started his career at the International Atomic Energy Agency (IAEA) in 1985, before moving to the German Animal Health Federation (BfT), a member association of the German Chemical Industry Association (VCI), in 1987.
Stefan Oschmann studied veterinary medicine at Ludwig-Maximilians-Universität in Munich from 1977 to 1982 and earned a doctorate there in 1985. He is married and has two children.